4.3 Article

Synthesis of a Human Urate Transporter-1 Inhibitor, an Arginine Vasopressin Antagonist, and a 17β-Hydroxysteroid Dehydrogenase Type-3 Inhibitor, Using Ring-Expansion of Cyclic Ketoximes with DIBALH

Journal

CHEMICAL & PHARMACEUTICAL BULLETIN
Volume 62, Issue 4, Pages 354-363

Publisher

PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/cpb.c13-00961

Keywords

diisobutylaluminum hydride; ring-expansion rearrangement; cyclic oxime; urate transporter-1 (URAT-1) inhibitor; arginine vasopressin (AVP) antagonist; 17 beta-hydroxysteroid dehydrogenase type-3 (17 beta-HSD3) inhibitor

Funding

  1. KAKENHI [23590001]
  2. Cabinet Office, Government of Japan
  3. Ministry of Education, Culture, Sports, Science and Technology of Japan
  4. JSPS
  5. Japan Tobacco Inc.
  6. Banyu Life Science Foundation International
  7. Grants-in-Aid for Scientific Research [26253001, 23590001] Funding Source: KAKEN

Ask authors/readers for more resources

Synthesis of three clinical candidates for medicines, a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17 beta-hydroxysteroid dehydrogenase type-3 inhibitor, is described. These compounds were synthesized via construction of their 3,4-dihydro-2H-benzo[b][1,4]oxazine, dibenzodiazepine, and dibenzazocine skeletons, respectively, using the reductive ring-expansion reaction of the corresponding bicyclic or tricyclic oximes with diisobutylaluminum hydride.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available